ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1047

Rates Of Hospitalized Infections In Rheumatoid Arthritis Patients From 5 Rheumatoid Arthritis Registries Across The World

Hisashi Yamanaka1, Johan Askling2, Niklas Berglind3, Stefan Franzén3, Thomas Frisell4, Christopher Garwood5, Jeffrey D. Greenberg6, Meilien Ho7, Marie Holmqvist2, Laura Horne8, Eisuke Inoue1, Kathy Lampl9, Kaleb Michaud10, Dimitrios A. Pappas11, George Reed12, Deborah Symmons5, Eiichi Tanaka13, Trung Tran14, Suzanne Verstappen5 and Fredrik Nyberg15, 1Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, 2Karolinska Institutet, Stockholm, Sweden, 3AstraZeneca R&D Mölndal, Mölndal, Sweden, 4Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, 5Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, 6New York Hospital for Joint Disease, New York, NY, 7AstraZeneca R&D Alderley Park, Macclesfield, United Kingdom, 8AstraZeneca, Wilmington, DE, 9AstraZeneca R&D Wilmington, Wilmington, DE, 10University of Nebraska Medical Center, Omaha, NE, 11Columbia University, New York, NY, 12University of Massachusetts Medical School, Worcester, MA, 13Tokyo Women's Medical University, Tokyo, Japan, 14MedImmune LLC, Gaithersburg, MD, 15AstraZeneca R&D, Mölndal, Sweden

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Epidemiologic methods, infection and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Title: Epidemiology and Health Services II & III

Session Type: Abstract Submissions (ACR)

Background/Purpose:  Rheumatoid arthritis (RA) patients are at increased risk of infection due to both RA itself and immunomodulating treatments. Infection rates are often difficult to compare across studies, since the rates may vary across the world, and due to methodological and demographic differences between studied populations or cohorts. We investigated rates of hospitalized infection in 5 RA registries from 4 continents, employing a standard set of analyses and standardizing rates to a common population.

Methods: Participating registries were CORRONA (USA), SRR (Sweden), NOAR (UK), CORRONA International (East Europe, Latin America, India) and IORRA (Japan). The definition of hospitalized infections was harmonized as much as possible across registries. Within each registry, we analyzed a primary cohort of all RA patients from January 2000 to last available data of each registry (2010-2013), and several subcohorts for sensitivity analyses, defined by disease activity, treatment status, calendar time, duration of follow-up and prior comorbidity. Rates were standardized for age, sex and, in 1 sensitivity analysis, also for HAQ, using the distributions from a typical RA trial program population.

Results: There was relatively high consistency in rates across registries, and sex/age standardization increased consistency further (Table 1). Generally, the primary cohorts provided the lowest or close to lowest rate (Table 2). In most registries, the highest rates were seen in subcohorts (either biologic naïve or with prior biologic treatment) with only 18 months follow-up after treatment change (Table 2). Additional standardization for HAQ score according to a trial patient distribution led to increased rates in all registries (Table 2).

Conclusion: This study constitutes the first attempt to compare the incidence of hospitalized infections internationally using existing RA cohorts. Consistent methodology, outcome definitions and analysis with standardization of rates facilitated comparison across registries. In most registries there is evidence of higher infection rates initially after starting treatment. The main analysis may be a good averaged estimate of risk over the longer term but may underestimate short-term risk. HAQ standardization appears useful to further address potential bias due to differences between registries and a typical trial population. Remaining differences between registries may reflect true regional differences in risk factors, populations and health care, although residual population and methodological differences are possible.

 


Disclosure:

H. Yamanaka,

AstraZeneca, Abbott, AbbVie, Chugai, Takeda, Pfizer, Daiichi Sankyo, Mitsubishi Tanabe, Teijin, Nippon Kayaku, Taishotoyama, Bristol-Myers Squibb, Astellas, Eisai, MSD, Santen, GlaxoSmithKline, Asahikasei, Janssen,

2,

AstraZeneca, Abbott, AbbVie, Chugai, Takeda, Pfizer, Daiichi Sankyo, Mitsubishi Tanabe, Teijin, Nippon Kayaku, Bristol-Myers Squibb, Astellas, Eisai,

5,

Abbott, AbbVie, Chugai, Takeda, Pfizer, Mitsubishi Tanabe, Teijin, Bristol-Myers Squibb, Astellas, Eisai,

8;

J. Askling,

AstraZeneca,

2,

AstraZeneca,

5;

N. Berglind,

AstraZeneca, Bristol-Myers Squibb,

1,

AstraZeneca,

3;

S. Franzén,

AstraZeneca,

1,

AstraZeneca,

3;

T. Frisell,
None;

C. Garwood,
None;

J. D. Greenberg,

AstraZeneca, CORRONA, Pfizer,

5,

CorRRONA,

1;

M. Ho,

AstraZeneca,

3;

M. Holmqvist,
None;

L. Horne,

AstraZeneca,

1,

AstraZeneca,

3;

E. Inoue,
None;

K. Lampl,

AstraZeneca,

1,

AstraZeneca,

3;

K. Michaud,

University of Nebraska Medical Center and the National Data Bank for Rheumatic Diseases,

3;

D. A. Pappas,

Corrona,

3,

Novartis Pharmaceutical Corporation,

5,

Adjunct assistant professor at Columbia University,

6;

G. Reed,

Corrona,

3;

D. Symmons,

AstraZeneca,

2,

AstraZeneca,

5;

E. Tanaka,
None;

T. Tran,

Medimmune LLC,

3;

S. Verstappen,
None;

F. Nyberg,

AstraZeneca,

3,

AstraZeneca,

1.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/rates-of-hospitalized-infections-in-rheumatoid-arthritis-patients-from-5-rheumatoid-arthritis-registries-across-the-world/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology